What Dexcom's Quarter ended Sep 30, 2026 10-Q says: 1 signal
Dexcom filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses inventory issue.
Public (DXCM)Medical Equipment Manufacturing10,000+ employeesdexcom.comLinkedIn
Get Dexcom's live signals in Claude or ChatGPT, or by API
What changed at Dexcom this week? Use Autobound signals for dexcom.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 2
- Signals
- 2
Source: Autobound Signal API · 83 signals tracked for Dexcom · updated
10-Q · latest 2
What Dexcom's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 1 signal
Higher inventory reserve charges incurred from planned discontinuation of G6 manufacturing
DexCom incurred higher inventory reserve charges associated with the planned discontinuation of G6 manufacturing, which partially offset gross profit and gross margin gains in the third quarter of 2026.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 1 signal
DexCom incurs excess and obsolete inventory charges from planned discontinuation of G6 manufacturing
Gross margin and cost of sales were negatively impacted by higher excess and obsolete inventory charges associated with the planned phase-out of G6 manufacturing.
Earnings calls
Dexcom earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Worldwide revenue up 11% to $1.34B in Q3Worldwide revenue reached $1.34 billion, growing 11% reported and organic year-over-year. U.S. revenue totaled $970 million, up 14%, while international revenue generated $375 million with 5% growth. Gross margin improved 380 basis points to 65.1%, and operating margin expanded to 25.3%. | |
| Full-year revenue guidance raised to $5.20B to $5.25BFull-year 2026 revenue guidance was raised to a range of $5.20 billion to $5.25 billion, representing 12% to 13% growth. Management also increased non-GAAP operating margin guidance to approximately 24% and adjusted EBITDA margin to approximately 32%, while maintaining gross margin guidance at approximately 64%. | |
| Signed deal to acquire European distributor businessA deal was signed to acquire the business of its largest remaining distributor partner in Europe to transition to direct operations across high-potential European markets. The transaction is in the sign-to-close phase and is expected to close in 2027 with no financial impact in Q3 or Q4 2026. | |
| Redesigned Stelo app and international G7 rolloutA fully redesigned Stelo app was launched in Q3 featuring enhanced glucose insights, meal logging, and nutritional data. Internationally, the G7 15 Day system will officially launch in Canada in November 2026 following Health Canada clearance, with a launch in Japan planned for early 2027. | |
| Captured U.S. market share led by type 2 non-insulinMarket share was captured across the U.S. CGM market, driven by customers with type 2 diabetes not on insulin. Global new patient starts reached near-record levels in Q3, supporting upper-teens active base growth ahead of an anticipated Medicare type 2 non-insulin coverage decision. | |
| Commercial production initiated at Ireland manufacturing plantCommercial production was initiated on schedule at the manufacturing plant in Ireland, expanding global manufacturing capacity across Europe alongside existing plants in the U.S. and Asia Pacific. The facility startup is expected to cause a temporary overhead variance drag on gross margin in Q4 and early 2027 before volume ramps up. |
Signal API · MCP
Track Dexcom with the Signal API
One POST /v1/companies/enrich call with dexcom.com returns Dexcom 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"dexcom.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Dexcom 10-Q
When did Dexcom file its latest 10-Q?
What did Dexcom disclose in its latest 10-Q?
What did Dexcom say on its recent earnings calls?
Where can I read Dexcom's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .